International Journal of Drug Delivery Technology
Volume 14, Issue 1

Evaluation of Growth-differentiation Factor-15 Level and few Physiological Parameters Patients with Diabetes Mellitus Type 2

Hassan A Farman, Raad R Naji*

Department of Pathological Analysis Techniques, College of Health & Medical Techniques, Al-Furat Al-Awsat Technical University, Iraq. 

Received: 05th October, 2023; Revised: 05th November, 2023; Accepted: 12th December, 2023; Available Online: 25th March, 2024

ABSTRACT

The study included 90 subjects and is divided into two groups: The first group is the patient group, which consists of 45 patients with diabetes mellitus type two; 45 patients with diabetes mellitus type two were identified by specialized diabetes doctors by samples collection in outpatients clinic at Diabetes and Endocrine Center in Marjan Medical City in Hilla city, Babylon province from 1 November 2022 till 31 Januray 2023. The blood samples of this study were obtained from patients and controlled through drug 5 mL of blood by using medical sterile syringes from a brachial vein and placed in a gel tube and ethylenediaminetetraacetic acid (EDTA) tube. Then the gel tube was placed at room temperature for 30 minutes to coagulate the blood, and samples were centrifuged (3000 rpm/min) for 5 minutes to separate the serum from other components of the blood. The serum was withdrawn by micropipette and then placed in the eppendorf tubes in two repeaters and kept frozen at

-20℃ for the determination of growth differentiation factor 15 (GDF 15), lipid profile and fasting blood glucose. The whole blood in the EDTA tube to determine HbA1C. The mean fasting blood sugar and hemoglobin A1c of diabetes patients is significantly higher at (p-value < 0.001) than that of controls. Diabetes patients had a significantly higher of serum lipid profile than the controls. Therefore, the mean of cholesterol, triglyceride, and low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) was highly significant (p < 0.001). The mean concentration of GDF-15 of patient groups was significantly increased than those matched groups of healthy control at (p < 0.001). In addition, the results also showed a highly significant increase (p < 0.001) in the mean of GDF-15 for the patient’s males and females in comparison with the control’s males and females. The correlation results indicated a statistically significant positive correlation in diabetic group between GDF-15 vs. FBS (r = 0.572, p = < 0.001) and HbA1c (r = 0.576, p = < 0.001). Positive non-significant correlations were demonstrated between GDF-15 vs. cholesterol (r = 0.131, p = > 0.05), triglyceride (TG) (r = 0.167, p = > 0.05), LDL (r = 0.38, p = > 0.05) and VLDL (r = 0.136, p = > 0.05). Negative non-significant correlation was between GDF-15 and high-density lipoprotein (HDL) (r = 0.137, p = > 0.05).

Keywords: GDF-15, Type 2 diabetes mellitus, Adipokines.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.63

How to cite this article: Farman HA, Naji RR. Evaluation of Growth-differentiation Factor-15 Level and few Physiological Parameters Patients with Diabetes Mellitus Type 2. International Journal of Drug Delivery Technology. 2024;14(1):442-446.

REFERENCES

  1. Roden M, & Shulman The integrative biology of type 2 diabetes. Nature, 2019: 576(7785), 51-60.f
  2. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi, H, Uribe KB, ., Martín Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences, 2020: 21(17), 6275.f
  3. Eddy AC, Trask Growth differentiation factor-15 and its role in diabetes and cardiovascular disease. Cytokine & growth factor reviews, 2021: 57, 11-18.f
  4. Wischhusen J, Melero I, & Fridman Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Frontiers in Immunology, 2020: 11, 951-960.f
  5. Kempf T, Guba-Quint A, Torgerson J, Magnone MC, Haefliger C, Bobadilla M, Wollert KC. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS European Journal of Endocrinology, 2012: 167(5), 671-678.f
  6. Sarkar S, Legere S, Haidl I, Marshall J, MacLeod JB, Aguiar C, Légaré JF. Serum GDF-15, a promising biomarker in obese patients undergoing heart surgery. Frontiers in cardiovascular medicine, 2020: 7, 103-108.f
  7. Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Anstee Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Science translational medicine, 2020: 12(572), eaba4448.f
  8. Wang J, Wei L, Yang X, Zhong Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. Journal of the American Heart Association, 2019: 8(17), e012826.f
  9. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L, Brown DA. Macrophage inhibitory cytokine‐1 (MIC‐1/GDF-15): a new marker of all‐cause mortality. Aging cell, 2010: 9(6), 1057-1064.f
  10. Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, Bing C. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology, 2009: 150(4), 1688-1696.f
  11. Abbas HH, Al-Alwany AA, Dleikh FS. Impact of smoking on cardiac electrophysiological parameters of symptomatic sinus node patients in Iraq. Pakistan Journal of Medical and Health Sciences, 2020: 14 (4), 1643 – 1650.
  12. Al Alwany AA. Echocardiographic Assessment of the Aortic Stenosis Valve Area: Parameters and Outcome, Journal of Medicinal and Chemical Sciences, 2022: 5 (7), 1281-1288, 26655/JMCHEMSCI.2022.7.17
  13. Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lipids in health and disease, 2014: 13, 1-6.
  14. Di Pino A, DeFronzo Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. Endocrine reviews, 2019: 40(6), 1447-1467.
  15. Daryabor, G, Atashzar, MR, Kabelitz D, Meri S, and Kalantar The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Frontiers in immunology, 2020: 11, 1582-1589.
  16. Patel BJ, Dave B, Dave D, Karmakar P, Shah M, and Sarvaiya Comparison and correlation of glucose levels in serum and saliva of both diabetic and non-diabetic patients. Journal of international oral health: JIOH, 2015: 7(8), 70-77.
  17. Carstensen M, Herder C, Brunner EJ, Strassburger K, Tabak A G, Roden M, Witte DR. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II European Journal of Endocrinology, 2010: 162(5), 913-917.
  18. Hong JH, Chung, HK, Park HY, Joung KH, Lee JH, Jung, JG, Shong M. GDF-15 is a novel biomarker for impaired fasting glucose. Diabetes & metabolism journal, 2014: 38(6), 472-479.
  19. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. The American journal of cardiology, 2014: 114(6), 890-894.
  20. Shin MY, Kim JM, Kang YE, Kim MK, Joung KH, Lee JH, Shong Association between growth differentiation factor 15 (GDF-15) and cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus. Journal of Korean Medical Science, 2016: 31(9), 1413-1418.
  21. Adela R, Mohammed SA, Kanwal A, Vishwakarma G, Chander Reddy PN, Banerjee Elevated levels of GDF-15 is associated with increased angiotensin II in hypertensive patients with Type 2 diabetes. Personalized medicine, 2016: 13(4), 325-336.
  22. Carlsson AC, Nowak C, Lind L, Östgren CJ, Nyström FH, Sundström J, Ärnlöv J. Growth differentiation factor 15 (GDF- 15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: A proteomics approach. Upsala Journal of Medical Sciences, 2020: 125(1), 37-43.
  23. Vila G, Riedl M, Anderwald C, Resl M, Handisurya A, Clodi M, and Luger The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clinical Chemistry, 2011: 57(2), 309-316.
  24. Nassar AM, Salim YM, Eid KS, Shaheen HM, Saati AA, Hetta HF, Batiha GS. Ameliorative effects of honey, propolis, pollen,and royal jelly mixture against chronic toxicity of sumithion insecticide in white albino rats. Molecules, 2020: 25(11), 2633.
  25. Adeyemi OS, Eseola AO, Plass W, Atolani O, Sugi T, Han Y, andKayode Imidazole derivatives as antiparasitic agents and use of molecular modeling to investigate the structure–activity relationship. Parasitology research, 2020: 119, 1925-1941.